FDA approves new version of plasma therapy from Talecris
Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. – The U.S. Food and Drug Administration has approved a new blood plasma-based therapeutic from Talecris Biotherapeutics (Nasdaq: TLCR) that targets a condition known as Alpha-1.
Talecris developed a new version of a 20-year-old product called Prolastin that helps victims of the alpha 1-antitrypsin deficiency prevent the onset of emphysema. Alpha-1 is a genetic disorder.
Called Prolastin-C, the new therapy bolsters protein levels with half the volume and in half the time than required by the earlier version.
"The introduction of Prolastin revolutionized care for thousands of individuals with Alpha-1," said John Walsh, chief executive officer of the Alpha-1 Foundation. "We welcome Prolastin-C as an example of the ongoing commitment Talecris has made to the Alpha-1 community."
Talecris was able to improve Prolastin through manufacturing techniques focused on a virus exclusion technology and an additional purification step. It is based on blood plasma.
Please log in to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- NC Biotech Center braces for worst as Senate slashes budget, too
- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows